Position in ZYME
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$5,956,740
+$2,769,125 QoQ
Shares Held
237,889
+96.5% QoQ
Ownership
0.326%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2023
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ZYME Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026HRT FINANCIAL LP holds $422,126,766 across 199 Biotechnology names. ZYME ranks #19 (1.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
128,633 | $42,560,800 | |
| 2 | IBRX |
ImmunityBio, Inc.
|
3,925,446 | $30,108,170 | |
| 3 | EXEL |
Exelixis, Inc.
|
460,585 | $19,754,490 | |
| 4 | IONS |
Ionis Pharmaceuticals Inc
|
252,250 | $18,941,452 | |
| 5 | MRNA |
Moderna, Inc.
|
368,421 | $18,715,786 | |
| 6 | ARGX |
Argenx SE
|
18,754 | $13,695,108 | |
| 7 | RARE |
Ultragenyx Pharmaceutical Inc.
|
613,229 | $12,847,147 | |
| 8 | IOVA |
Iovance Biotherapeutics, Inc.
|
3,486,299 | $12,236,909 |
All Filings in ZYME
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $5,956,740 | 237,889 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $3,187,615 | 121,064 | Shares | Defined | 2026-02-12 | |
| 2025-09-30 | $1,169,313 | 68,461 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $411,112 | 32,758 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $778,675 | 65,380 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $1,405,059 | 95,974 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $612,540 | 48,808 | Shares | Defined | 2024-11-12 | |
| 2023-03-31 | $2,956,315 | 327,026 | Shares | Defined | 2023-05-12 | |
| No filing history on record for this holder in this stock. | ||||||